Pharmacogenomics of ABC transporters and its role in cancer chemotherapy

Drug Resistance Updates

Volumn 6, Issue 2, 2003, Pages 71-84

  Sparreboom, Alex ^a   Danesi, Romano ^b   Ando, Yuichi ^a,c   Chan, Juliana ^a,d   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ABC transporters; Chemotherapy; Pharmacogenetics; Polymorphisms

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CHLORAMBUCIL; CLOTRIMAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; DYE; ETOPOSIDE; GENE PRODUCT; GLUTATHIONE; GLYCOPROTEIN P; LEUKOTRIENE C4; MITOXANTRONE; MITOXANTRONE RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN; RADIXIN; TACROLIMUS; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCRISTINE;

ANION TRANSPORT; BLOOD BRAIN BARRIER; CANCER CELL; CANCER CHEMOTHERAPY; CELL TYPE; CHROMOSOME 10Q; CHROMOSOME 16P; CHROMOSOME 7Q; DENDRITIC CELL; DETOXIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; DUBIN JOHNSON SYNDROME; EPITHELIUM CELL; EXON; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; KNOCKOUT MOUSE; MISSENSE MUTATION; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; RHABDOMYOSARCOMA; SHORT SURVEY; WILD TYPE;

EID: 0037988709     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(03)00005-0     Document Type: Short Survey

References (135)

1. Allen, J.D., Schinkel, A.H., 2002. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. 1, 427-434.
2. Allen, J.D., Brinkhuis, R.F., Wijnholds, J., Schinkel, A.H., 1999. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59, 4237-4241.
3. Allen, J.D., Brinkhuis, R.F., van Deemter, L., Wijnholds, J., Schinkel, A.H., 2000. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 60, 5761-5766.
4. Allen, J.D., Jackson, S.C., Schinkel, A.H., 2002a. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res. 62, 2294-2299.
5. Allen, J.D., van Loevezijn, A., Lakhai, J.M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J.H., Koomen, G.J., Schinkel, A.H., 2002b. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1, 417-425.
6. Allikmets, R., Schriml, L.M., Hutchinson, A., Romano-Spica, V., Dean, M., 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339.
7. Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I., Gottesman, M.M., 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398.
8. Ameyaw, M.M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., Thornton, N., Folayan, G.O., Githang'a, J., Indalo, A., Ofori-Adjei, D., Price-Evans, D.A., McLeod, H.L., 2001. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11, 217-221.
9. Bardelmeijer, H.A., Ouwehand, M., Buckle, T., Huisman, M.T., Schellens, J.H., Beijnen, J.H., van Tellingen, O., 2002. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 62, 6158-6164.
10. Bates, S.E., Robey, R., Miyake, K., Rao, K., Ross, D.D., Litman, T., 2001. The role of half-transporters in multidrug resistance. J. Bioenerg. Biomembr. 33, 503-511.
11. Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., Funk-Bretano, C., 2001. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70, 311-316.
12. Bernard, P.S., Wittwer, C.T., 2002. Real-time PCR technology for cancer diagnostics. Clin. Chem. 48, 1178-1185.
13. Borst, P., Evers, R., Kool, M., Wijnholds, J., 2000. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-1302.
14. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., Bates, S.E., 1999. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59, 5938-5946.
15. Brinkmann, U., Eichelbaum, M., 2001. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenom. J. 1, 59-64.
16. Brinkmann, U., Roots, I., Eichelbaum, M., 2001. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today 6, 835-839.
17. Cascorbi, I., Gerloff, T, Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., Schaeffeler, E., Eichelbaum, M., Brinkmann, U., Roots, I., 2001. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69, 169-174.
18. Chaudhary, P.M., Roninson, I.B., 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85-94.
19. Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M., Roninson, I.B., 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistance human cells. Cell 47, 381-389.
20. Chowbay, B., Cumaraswamy, S., Cheung, Y.B., Zhou, Q., Lee, E.J.D., 2003. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13, 89-95.
21. Cocker, H.A., Tiffin, N., Pritchard-Jones, K., Pinkerton, C.R., Kelland, L.R., 2001. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin. Cancer Res. 7, 3193-3198.
22. Cole, S.P., Deeley, R.G., 1998. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20, 931-940.
23. Cole, S.P., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., Stewart, A.J., Kurz, E.U., Duncan, A.M., Deeley, R.G., 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654.
24. Conrad, S., Kauffmann, H.M., Ito, K., Deeley, R.G., Cole, S.P., Schrenk, D., 2001. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 46, 656-663.
25. Conrad, S., Kauffmann, H.M., Ito, K., Leslie, E.M., Deeley, R.G., Schrenk, D., Cole, S.P., 2002. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12, 321-330.
26. Cotton, R.G.H., Horaitis, O., 2002. The HUGO mutation database initiative. Pharmacogenom. J. 2, 16-19.
27. Danesi, R., De Braud, F., Fogli, S., Di Paolo, A., Del Tacca, M., 2001. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci. 22, 420-426.
28. Danesi, R., De Braud, F., Fogli, S., De Pas, M., Di Paolo, A., Curigliano, G., Del Tacca, M., 2003. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol. Rev. 55, 57-103.
29. de Bruin, M., Miyake, K., Litman, T., Robey, R., Bates, S.E., 1999. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 146, 117-126.
30. Dean, M., 2002. The human ATP-binding cassette (ABC) transporter superfamily. NCBI Monographs. National Library of Medicine, Bethesda, MD, USA.
31. Desai, D.G., Murayama, N., Lantz, M., Woo, J.M., Chan, W., Benet, L.Z., 2003. The functional change of P-glycoprotein on lymphocytes under induction conditions as a function of MDR1 polymorphisms. Clin. Pharmacol. Ther. 73, P13 (abstract).
32. Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K., Ross, D.D., 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 15665-15670.
33. Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M., Fromm, M.F., 2002. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53, 526-534.
34. Dürr, D., Stieger, B., Kullak-Ublick, G.A., Rentsch, K.M., Steinert, H.C., Meier, P.J., Fattinger, K., 2000. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68, 598-604.
35. Evans, W.E., McLeod, H.L., 2003. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549.
36. Faneyte, I.F., Kristel, P.M., Maliepaard, M., Scheffer, G.L., Scheper, R.J., Schellens, J.H., van de Vijver, M.J., 2002. Expression of the breast cancer resistance protein in breast cancer. Clin. Cancer Res. 8, 1068-1074.
37. Felici, A., Verweij, J., Sparreboom, A., 2002. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur. J. Cancer 38, 1677-1684.
38. Fellay, J., Marzolini, C., Meaden, E.R., Back, D.J., Buclin, T., Chave, J.P., Decosterd, L.A., Furrer, H., Opravil, M., Pantaleo, G., Retelska, D., Ruiz, L., Schinkel, A.H., Vernazza, P., Eap, C.B., Telenti, A., 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36.
39. Fromm, M.F., 2002. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54, 1295-1310.
40. Fromm, M.F., Kauffmann, H.M., Fritz, P., Burk, O., Kroemer, H.K., Warzok, R.W., Eichelbaum, M., Siegmund, W., Schrenk, D., 2000. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157, 1575-1580.
41. Garner, R.C., Goris, I., Laenen, A.A., Vanhoutte, E., Meuldermans, W., Gregory, S., Garner, J.V., Leong, D., Whattam, M., Calam, A., Snel, C.A., 2002. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 30, 823-830.
42. Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., Roots, I., 2002. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 54, 610-616.
43. Goh, B.C., Lee, S.C., Wang, L.Z., Fan, L., Guo, J.Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.L., Ong, A.B., Lee, H.S., 2002. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20, 3683-3690.
44. Goto, M., Masuda, S., Saito, H., Uemoto, S., Kiuchi, T., Tanaka, K., Inui, K., 2002. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12, 451-457.
45. Gottesman, M.M., Fojo, T., Bates, S.E., 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
46. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., von Richter, O., Zundler, J., Kroemer, H.K., 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153.
47. Hanash, S.M., 2001. Global profiling of gene expression in cancer using genomics and proteomics. Curr. Opin. Mol. Ther. 3, 538-545.
48. Hitzl, M., Drescher, S., van der Kuip, H., Schaffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., Fromm, M.F., 2001. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11, 293-298.
49. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., Brinkmann, U., 2000a. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473-3478.
50. Honjo, Y., Hrycyna, C.A., Yan, Q.W., Medina-Perez, W.Y., Robey, R.W., van de Laar, A., Litman, T., Dean, M., Bates, S.E., 2001. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61, 6635-6639.
51. Huang, J.X., Mehrens, D., Wiese, R., Lee, S., Tam, S.W., Daniel, S., Gilmore, J., Shi, M., Lashkari, D., 2001. High-throughput genomic and proteomic analysis using microarray technology. Clin. Chem. 47, 1912-1916.
52. Hutter, G., Sinha, P., 2001. Proteomics for studying cancer cells and the development of chemoresistance. Proteomics 1, 1233-1248.
53. Hyde, S.C., Emsley, P., Hartshorn, M.J., Mimmack, M.M., Gileadi, U., Pearce, S.R., Gallagher, M.P., Gill, D.R., Hubbard, R.E., Higgins, C.F., 1990. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346, 362-365.
54. Iida, A., Saito, S., Sekine, A., Mishima, C., Kitamura, Y., Kondo, K., Harigae, S., Osawa, S., Nakamura, Y., 2002. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet. 47, 285-310.
55. Illmer, T., Schuler, U.S., Thiede, C., Schwarz, U.I., Kim, R.B., Gotthard, S., Freund, D., Schakel, U., Ehninger, G., Schaich, M., 2002. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62, 4955-4962.
56. Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y., Sugimoto, Y., 2002. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616.
57. Ito, K., Olsen, S.L., Qiu, W., Deeley, R.G., Cole, S.P., 2001. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J. Biol. Chem. 276, 15616-15624.
58. Itoda, M., Saito, Y., Soyama, A., Saeki, M., Murayama, N., Ishida, S., Sai, K., Nagano, M., Suzuki, H., Sugiyama, Y., Ozawa, S., Sawada Ji, J., 2002. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30, 363-364.
59. Iyer, L., Ramirez, J., Shepard, D.R., Bingham, C.M., Hossfeld, D.K., Ratain, M.J., Mayer, U., 2002. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 49, 336-341.
60. Johne, A., Kopke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M.F., Brinkmann, U., Eichelbaum, M., Brockmoller, J., Cascorbi, I., Roots, I., 2002. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594.
61. Jonker, J.W., Smit, J.W., Brinkhuis, R.F., Maliepaard, M., Beijnen, J.H., Schellens, J.H., Schinkel, A.H., 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92, 1651-1656.
62. Jonker, J.W., Buitelaar, M., Wagenaar, E., Van Der Valk, M.A., Scheffer, G.L., Scheper, R.J., Plosch, T., Kuipers, F., Elferink, R.P., Rosing, H., Beijnen, J.H., Schinkel, A.H., 2002. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99, 15649-15654.
63. Kehrer, D.F., Mathijssen, R.H., Verweij, J., de Bruijn, P., Sparreboom, A., 2002. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 20, 3122-3129.
64. Keitel, V., Kartenbeck, J., Nies, A.T., Spring, H., Brom, M., Keppler, D., 2000. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32, 1317-1328.
65. Keitel, V., Nies, A.T., Brom, M., Hummel-Eisenbeiss, J., Spring, H., Keppler, D., 2003. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am. J. Physiol. Gastrointest. Liver Physiol. 284, G165-G174.
66. Kerb, R., Aynacioglu, A.S., Brockmoller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgartner, C., Ongen, H.Z., Guzelbey, P., Roots, I., Brinkmann, U., 2001a. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenom. J. 1, 204-210.
67. Kerb, R., Hoffmeyer, S., Brinkmann, U., 2001b. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2, 51-64.
68. Kielar, D., Dietmaier, W., Langmann, T., Aslanidis, C., Probst, M., Naruszewicz, M., Schmitz, G., 2001. Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin. Chem. 47, 2089-2097.
69. Kikuchi, S., Hata, M., Fukumoto, K., Yamane, Y., Matsui, T., Tamura, A., Yonemura, S., Yamagishi, H., Keppler, D., Tsukita, S., 2002. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat. Genet. 31, 320-325.
70. Kim, R.B., Leake, B.F., Choo, E.F., Dresser, G.K., Kubba, S.V., Schwarz, U.I., Taylor, A., Xie, H.G., McKinsey, J., Zhou, S., Lan, L.B., Schuetz, J.D., Schuetz, E.G., Wilkinson, G.R., 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199.
71. Kimchi-Sarfaty, C., Gribar, J.J., Gottesman, M.M., 2002. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1-6.
72. Kool, M., de Haas, M., Scheffer, G.L., Scheper, R.J., van Eijk, M.J., Juijn, J.A., Baas, F., Borst, P., 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57, 3537-3547.
73. Kruijtzer, C.M., Beijnen, J.H., Rosing, H., ten Bokkel Huinink, W.W., Schot, M., Jewell, R.C., Paul, E.M., Schellens, J.H., 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20, 2943-2950.
74. Kudoh, K., Ramanna, M., Ravatn, R., Elkahloun, A.G., Bittner, M.L., Meltzer, P.S., Trent, J.M., Dalton, W.S., Chin, K.V., 2000. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161-4166.
75. Kurata, Y., Ieiri, I., Kimura, M., Morita, T., Irie, S., Urae, A., Ohdo, S., Ohtani, H., Sawada, Y., Higuchi, S., Otsubo, K., 2002. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72, 209-219.
76. Leonard, G.D., Polgar, O., Bates, S.E., 2002. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Invest. Drugs 3, 1652-1659.
77. Lin, J.H., Yamazaki, M., 2003. Role of P-glycoprotein in pharmaco-kinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98.
78. Litman, T., Druley, T.E., Stein, W.D., Bates, S.E., 2001. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58, 931-959.
79. Lorico, A., Rappa, G., Finch, R.A., Yang, D., Flavell, R.A., Sartorelli, A.C., 1997. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. 57, 5238-5242.
80. Macphee, I.A., Fredericks, S., Tai, T., Syrris, P., Carter, N.D., Johnston, A., Goldberg, L., Holt, D.W., 2002. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74, 1486-1489.
81. Maliepaard, M., Scheffer, G.L., Faneyte, I.F., van Gastelen, M.A., Pijnenborg, A.C., Schinkel, A.H., van De Vijver, M.J., Scheper, R.J., Schellens, J.H., 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464.
82. Malingre, M.M., Beijnen, J.H., Schellens, J.H., 2001. Oral delivery of taxanes. Invest. New Drugs 19, 155-162.
83. Mathijssen, R.H., Loos, W.J., Verweij, J., Sparreboom, A., 2002a. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2, 103-123.
84. Mathijssen, R.H.J., Xie, R., McLeod, H.L., Verweij, J., Palmer, P., Karlsson, M.O., Sparreboom, A., 2002b. Pharmacokinetic and pharmacogenetic analysis of irinotecan (CPT-11) in combination with R115777. Eur. J. Cancer 38, S44 (abstract).
85. Mickley, L.A., Lee, J.S., Weng, Z., Zhan, Z., Alvarez, M., Wilson, W., Bates, S.E., Fojo, T., 1998. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91, 1749-1756.
86. Min, D.I., Ellingrod, V.L., 2002. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 24, 400-404.
87. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., Bates, S.E., 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13.
88. Moriya, Y., Nakamura, T., Horinouchi, M., Sakaeda, T., Tamura, T., Aoyama, N., Shirakawa, T., Gotoh, A., Fujimoto, S., Matsuo, M., Kasuga, M., Okumura, K., 2002. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNAS expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull 25, 1356-1359.
89. Nakamura, T., Sakaeda, T., Horinouchi, M., Tamura, T., Aoyama, N., Shirakawa, T., Matsuo, M., Kasuga, M., Okumura, K., 2002. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71, 297-303.
90. Ohishi, Y., Oda, Y., Uchiumi, T., Kobayashi, H., Hirakawa, T., Miyamoto, S., Kinukawa, N., Nakano, H., Kuwano, M., Tsuneyoshi, M., 2002. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 8, 3767-3775.
91. Paulusma, C.C., Bosma, P.J., Zaman, G.J., Bakker, C.T., Otter, M., Scheffer, G.L., Scheper, R.J., Borst, P., Oude Elferink, R.P., 1996. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271, 1126-1128.
92. Paulusma, C.C., Kool, M., Bosma, P.J., Scheffer, G.L., ter Borg, F., Scheper, R.J., Tytgat, G.N., Borst, P., Baas, F., Oude Elferink, R.P., 1997. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25, 1539-1542.
93. Putnam, W., Desai, D.G., Huang, Y., Woo, J.M., Benet, L.Z., 2003. The effect of induction conditions and MDR1 genotypes on dicloxacillin pharmacokinetics. Clin. Pharmacol. Ther. 73, P57 (abstract).
94. Rabindran, S.K., Ross, D.D., Doyle, L.A., Yang, W., Greenberger, L.M., 2000. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60, 47-50.
95. Randolph, G.J., Beaulieu, S., Pope, M., Sugawara, I., Hoffman, L., Steinman, R.M., Muller, W.A., 1998. A physiologic function for P-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. U.S.A. 95, 6924-6929.
96. Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., Snyder, A.Z., Finch, R.A., Sartorelli, A.C., Piwnica-Worms, D., 1999. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U.S.A. 96, 3900-3905.
97. Ratnasinghe, D., Daschner, P.J., Anver, M.R., Kasprzak, B.H., Taylor, P.R., Yeh, G.C., Tangrea, J.A., 2001. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance is chemoprevention against multidrug resistance possible? Anticancer Res. 21, 2141-2147.
98. Richardson, M.A., Straus, S.E., 2002. Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin. Oncol. 29, 531-545.
99. Robbiani, D.F., Finch, R.A., Jager, D., Muller, W.A., Sartorelli, A.C., Randolph, G.J., 2000. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103, 757-768.
100. Roberts, R.L., Joyce, P.R., Mulder, R.T., Begg, E.J., Kennedy, M.A., 2002. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2, 191-196.
101. Robey, R.W., Honjo, Y., van de Laar, A., Miyake, K., Regis, J.T., Litman, T., Bates, S.E., 2001. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys. Acta 1512, 171-182.
102. Rocchi, E., Khodjakov, A., Volk, E.L., Yang, C.H., Litman, T., Bates, S.E., Schneider, E., 2000. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. 271, 42-46.
103. Ross, D.D., Yang, W., Abruzzo, L.V., Dalton, W.S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S.P., Doyle, L.A., 1999. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91, 429-433.
104. Saito, S., Iida, A., Sekine, A., Miura, Y., Ogawa, C., Kawauchi, S., Higuchi, S., Nakamura, Y., 2002a. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J. Hum. Genet. 47, 147-171.
105. Saito, S., Iida, A., Sekine, A., Miura, Y., Ogawa, C., Kawauchi, S., Higuchi, S., Nakamura, Y., 2002b. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47, 38-50.
106. Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., Kasuga, M., Okumura, K., 2001. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Aaps. Pharmsci. 3, 3.
107. Schaeffeler, E., Eichelbaum, M., Brinkmann, U., Penger, A., Asante-Poku, S., Zanger, U.M., Schwab, M., 2001. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358, 383-384.
108. Schellens, J.H., Malingre, M.M., Kruijtzer, C.M., Bardelmeijer, H.A., van Tellingen, O., Schinkel, A.H., Beijnen, J.H., 2000. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur. J. Pharm. Sci. 12, 103-110.
109. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., 1994. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502.
110. Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A., van Deemter, L., Smit, J.J., van der Valk, M.A., Voordouw, A.C., Spits, H., van Tellingen, O., Zijlmans, J.M., Fibbe, W.E., Borst, P., 1997. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 94, 4028-4033.
111. Schwab, M., Eichelbaum, M., Fromm, M.F., 2003. Genetic polymorphisms of the human mdrl drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307.
112. Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H.K., Cascorbi, I., 2002. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72, 572-583.
113. Siegsmund, M., Brinkmann, U., Schaeffeler, E., Weirich, G., Schwab, M., Eichelbaum, M., Fritz, P., Burk, O., Decker, J., Alken, P., Rothenpieler, U., Kerb, R., Hoffmeyer, S., Brauch, H., 2002. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13, 1847-1854.
114. Smit, J.W., Huisman, M.T., van Tellingen, O., Wiltshire, H.R., Schinkel, A.H., 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104, 1441-1447.
115. Sparreboom, A., Nooter, K., 2000. Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Updat. 3, 357-363.
116. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H., van Tellingen, O., 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 94, 2031-2035.
117. Sparreboom, A., Marsh, S., Mathijssen, R.H.J., Verweij, J., McLeod, H.L., 2002. Irinotecan (CPT-11) disposition in relation to single-nucleotide polymorphisms (SNPs) of ABC transporters and drug-metabolizing enzymes. Proc. Am. Soc. Clin. Oncol. 21, 83a (abstract).
118. Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., Takahashi, M., Kurata, Y., Kigawa, J., Higuchi, S., Terakawa, N., Otsubo, K., 2001. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297, 1137-1143.
119. Tang, K., Ngoi, S.M., Gwee, P.C., Chua, J.M., Lee, E.J., Chong, S.S., Lee, C.G., 2002. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12, 437-450.
120. Toh, S., Wada, M., Uchiumi, T., Inokuchi, A., Makino, Y., Horie, Y., Adachi, Y., Sakisaka, S., Kuwano, M., 1999. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64, 739-746.
121. van der Heiden, I.P., van den Heuvel, M.M., Wiemer, E., Pieters, R., Lindemans, J., van den Anker, J., van Schaik, R., 2003. MDR-1 C3435T gene polymorphism does not correlate with P-glycoprotein expression and function in acute myeloid leukemia. Clin. Pharmacol. Ther. 73, P58 (abstract).
122. van Schaik, R., Hesselink, D.A., van der Heiden, I.P., van der Werf, M., Lindemans, J., van Gelder, T., 2003. Tacrolimus, but not cyclosporine drug levels, are correlated with CYP3A5*3 and CYP3A4*1B genotype no correlation with the MDR-1 C3435T polymorphism. Clin. Pharmacol. Ther. 73, P56 (abstract).
123. van Zuylen, L., Verweij, J., Nooter, K., Brouwer, E., Stoter, G., Sparreboom, A., 2000. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin. Cancer Res. 6, 2598-2603.
124. Verstuyft, C., Strabach, S., El Morabet, H., Kerb, R., Brinkmann, U., Dubert, L., Jaillon, P., Funk-Brentano, C., Trugnan, G., Becquemont, L., 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73, 51-60.
125. von Ahsen, N., Richter, M., Grupp, C., Ringe, B., Oellerich, M., Armstrong, V.W., 2001. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47, 1048-1052.
126. Wada, M., Toh, S., Taniguchi, K., Nakamura, T., Uchiumi, T., Kohno, K., Yoshida, I., Kimura, A., Sakisaka, S., Adachi, Y., Kuwano, M., 1998. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 7, 203-207.
127. Weinshilboum, R., 2003. Inheritance and drug response. N. Engl. J. Med. 348, 529-537.
128. Weiss, S.T., Silverman, E.K., Palmer, L.J., 2001. Case-control association studies in pharmacogenetics. Pharmacogenom. J. 1, 157-158.
129. Westphal, K., Weinbrenner, A., Zschiesche, M., Franke, G., Knoke, M., Oertel, R., Fritz, P., von Richter, O., Warzok, R., Hachenberg, T., Kauffmann, H.M., Schrenk, D., Terhaag, B., Kroemer, H.K., Siegmund, W., 2000. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68, 345-355.
130. Wijnholds, J., Evers, R., van Leusden, M.R., Mol, C.A., Zaman, G.J., Mayer, U., Beijnen, J.H., van der Valk, M., Krimpenfort, P., Borst, P., 1997. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 3, 1275-1279.
131. Wijnholds, J., de Lange, E.C., Scheffer, G.L., van den Berg, D.J., Mol, C.A., van der Valk, M., Schinkel, A.H., Scheper, R.J., Breimer, D.D., Borst, P., 2000. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105, 279-285.
132. Yamauchi, A., Ieiri, I., Kataoka, Y., Tanabe, M., Nishizaki, T., Oishi, R., Higuchi, S., Otsubo, K., Sugimachi, K., 2002. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74, 571-572.
133. Zaman, G.J., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R.P., Baas, F., Borst, P., 1995. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. U.S.A. 92, 7690-7694.
134. Zamber, C.P., Lambda, J.K., Yasuda, K., Famum, J., Thummel, K., Schuetz, J.D., Schuetz, E.G., 2003. Natural allelic variants of breast cancer resistant protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13, 19-28.
135. Zhou, J., Higashi, K., Ueda, Y., Kodama, Y., Guo, D., Jisaki, F., Sakurai, A., Takegami, T., Katsuda, S., Yamamoto, I., 2001. Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer. J. Nucl. Med. 42, 1476-1483.